MRS Mammography Reporting System: Pricing, Owner and Alternatives

The short answer: MRS is now owned by Lunit. MRS Systems, Inc., the Seattle company founded in 1985 that built the Aspen Breast mammography reporting system, was acquired by Volpara Health in 2019. Lunit then acquired Volpara in May 2024 for roughly $194 million, and Aspen Breast was renamed Volpara Patient Hub. Existing MRS6, MRS7 and Aspen Breast installations continue to be supported under the Volpara name. If you are budgeting a renewal or a replacement, United States federal award records give the only public price anchors: a Defense Health Agency award for mammography reporting system support came in at $438,810, and two Veterans Affairs awards for Aspen Breast software and a VISN 8 upgrade were $136,000 each.

Updated September 2026. Contract figures are prime award records from USAspending.gov, retrieved September 6, 2026. Clearance counts are from the openFDA 510(k) database, retrieved the same day. These describe what federal buyers signed and what regulators have on file, which is a reference point rather than a quote for your facility.

Who owns MRS mammography reporting system now?

Lunit, a Korean medical AI company listed in Seoul, owns it through two acquisitions. The product most people still call MRS or Aspen Breast is sold today as Volpara Patient Hub. Nothing about the name change was hidden, but it happened in two steps five years apart, which is why buyers still search for the original name and land on a redirect.

The practical consequence is not the branding. It is that the roadmap for a breast imaging records system now sits inside a company whose core business is AI image analysis. That can be good news, because reporting and detection finally share an owner. It also means the reporting product competes for engineering attention against an AI portfolio, and you should ask directly where it sits in the investment plan before you sign a multi-year term.

Is Aspen Breast still supported?

Yes. Volpara stated at the time of the MRS acquisition that it would continue supporting MRS6, MRS7 and Aspen Breast customers, and the product line was carried forward rather than sunset. This is materially different from a vendor end of life, where renewals stop and a migration deadline is published. Nothing of that kind has been announced here.

That distinction matters because the two situations call for opposite responses. A sunset forces a migration on the vendor's timetable. An acquisition just changes who you negotiate with, which means your leverage at renewal is intact and you can take your time. If you are dealing with an actual announced sunset elsewhere in your stack, the pattern and the checklist are different, and our write-up of who owns radiology reporting software covers how the consolidation in this market tends to play out.

What does Volpara Patient Hub cost?

No mammography reporting vendor publishes a price list, so the honest answer is that public pricing does not exist. Federal contract records are the closest available substitute, because the government publishes what it signed and names the product in the award description.

Read these as ceilings for large multi-site institutional deployments, not as a single-site quote. The two $136,000 awards are three years apart and identical in value, which suggests a stable negotiated rate for that VISN rather than a coincidence. Note also that these awards now appear in USAspending under the recipient name Lunit Americas, Inc., because the recipient of record was updated after the acquisition. If you search the older company names you will find nothing, which is a good way to conclude a vendor has no federal history when in fact it has plenty.

For comparison against the main competitor in the same category, MagView deployments in federal records ran from $55,490 to $219,980, with annual support on an installed system between $61,853.98 and $134,922.10. The full award-by-award table sits on our mammography tracking software comparison, alongside what MQSA actually obliges the system to do.

What are the alternatives to MRS Aspen Breast?

The United States market for mammography tracking and reporting is small and stable. These are the systems that come up in real evaluations.

The clearance column is there to prevent a common misreading rather than to rank anyone. A zero is not a red flag in this category, and the eRAD entries are for its PACS rather than for tracking. Tracking and reporting software manages records, correspondence and audits, so it is not a diagnostic device and does not need a 510(k). Image analysis is the part that does: Volpara holds 2 clearances, ScreenPoint Medical 8, iCAD 15 and Hologic 127. If a tracking vendor demonstrates an AI feature during an evaluation, ask for the K number covering that specific feature.

Should you migrate or renew?

Migration cost in this category is dominated by one thing, and it is not the license. It is history. A tracking system's value is the years of correlated outcomes sitting inside it, and an MQSA medical outcomes audit reaches back across that history. Any migration plan that does not specify exactly which prior years move, in what structure, and who validates them against the old system is not a plan yet.

A reasonable test: ask the incoming vendor to migrate two full prior years into a sandbox and then reproduce your last signed outcomes audit from the migrated data. If the numbers match, the migration is real. If the vendor will only commit to moving forward-looking records, you are running two systems for several years and your true cost is both licenses plus the reconciliation work.

What to ask before you sign

Four questions separate a clean renewal from an expensive one. Where does this product sit in the roadmap now that the owner's core business is AI image analysis. What is the renewal escalator, and is it capped. Which prior years of outcome data migrate, and who validates them. And how do outside pathology results get into the record, since that is the step nobody automates well.

That last one deserves attention because it is where staff time actually goes. When a biopsy happens at another facility, the result usually arrives as a faxed or scanned PDF that someone rekeys into the tracking system, and the MQSA correlation is not complete until they do. Teams that fix this generally do it by extracting the structured data out of those scanned pathology documents automatically before it reaches the tracking system, rather than by buying a different tracker. The bottleneck is the document, not the database.

Where an AI assistant fits, and where it does not

Radiological.ai is not a mammography tracking system and does not replace one. Tracking is a records and correspondence obligation, and MQSA is specific about what it requires. What we do sits upstream, on the imaging side of the same workflow: triaging the worklist so suspected time-critical studies surface first, flagging suspected findings for the radiologist to review, and drafting the structured report into your own template with the assessment fields coded consistently. That consistency is what a tracking system depends on, because an outcomes audit is only as good as the assessments feeding it.

It is decision support. The radiologist reviews every flag and signs every report. If you are evaluating the detection layer that works on the images themselves, that is a separate product category with a separate regulatory path, and our AI mammography page covers it. If the reporting structure is the problem rather than the tracking, structured radiology reporting is the better starting point, and radiology software pricing benchmarks the rest of the imaging budget against the same federal award data used throughout this article.